Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...